echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > AstraZeneca/Mersk’s Lynparza combined with Roche Avastin is recommended in the UK for the treatment of ovarian cancer

    AstraZeneca/Mersk’s Lynparza combined with Roche Avastin is recommended in the UK for the treatment of ovarian cancer

    • Last Update: 2021-03-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Compile Ke Ke

    Recently, foreign media reported that the National Institute of Health Care Excellence (NICE) recommended AstraZeneca/Mersk’s Lynparza (Olabarib) and Roche’s Avastin (bevacizumab) through the Cancer Drug Fund (CDF).
    ), used for maintenance treatment of patients with homologous recombination defect (HRD) positive advanced ovarian, fallopian tube and peritoneal cancer that fully or partially respond to first-line platinum-based chemotherapy and bevacizumab.

    This recommendation is based on data from the phase 3 clinical study PAOLA-1.
    Compared with bevacizumab alone, olaparib combined with bevacizumab can reduce the risk of disease progression or death by 67%.
    The combination of olaparib and bevacizumab also increased the patient's progression-free survival (PFS) from 17.
    7 months to 37.
    2 months.

    In this study, about 48% of patients were newly diagnosed patients with HRD-positive advanced ovarian cancer.

    The British National Health System (NHS) supports the introduction of olaparib combined with bevacizumab therapy, and the organization is providing genomic HRD testing for patients who use the therapy for the first time.
    This test only examines a tumor sample to determine the HRD and somatic BRCA mutation status.

    Olabarib is known as a PARP inhibitor as an inhibitor of poly ADP ribose polymerase (PARP).
    BRCA1/2 mutations may be genetically prone to cause certain cancers, and may also be resistant to other cancer treatments.
    However, these cancers sometimes have a unique vulnerability because cancer cells increasingly rely on PARP to repair their DNA so that they can continue to divide.
    This means that if the cancer is susceptible to this treatment, drugs that selectively inhibit PARP may be beneficial.

    In December 2014, the European Medicines Agency (EMA) and the U.
    S.
    Food and Drug Administration (FDA) approved olaparib as a single drug.
    The US FDA approved the drug for use in advanced ovarian cancer with germline BRCA mutation (gBRCAm) that has received three or more chemotherapies.
    In January 2018, olaparib became the first PARP inhibitor approved by the US FDA for gBRCAm metastatic breast cancer.
    The drug was developed by the British biotechnology company KuDOS Pharmaceuticals and was first applied to patients.
    Since KuDOS was acquired by AstraZeneca in 2006, AstraZeneca and Merck have carried out clinical development of the drug.
    Olapali combined with temozolomide for relapse Small cell lung cancer has significant clinical activity.

    Reference source:

    1.
    Wikipedia

    2.
    NICE approves Lynparza plus Avastin via Cancer Drugs Fund

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.